PDCD1 and non-small cell lung carcinoma: The CheckMate 057 trial is a clinical trial that evaluated the efficacy and safety of nivolumab, a PD-1 programmed death-ligand inhibitor, compared to docetaxel in patients with previously treated advanced NSCLC.